
|Videos|November 17, 2016
- NSCLC (Issue 11)
- Volume 4
- Issue 2
Clinical Trials Exploring Bevacizumab in NSCLC
Author(s)Catherine Shu, MD
Catherine Shu, MD, medical oncologist, Division of Hematology/Oncology, Columbia University Medical Center, discusses two clinical trials exploring the use of bevacizumab (Avastin) in patients with non-small cell lung cancer.
Advertisement
Articles in this issue
over 9 years ago
Erlotinib Plus Bevacizumab in EGFR-Mutant NSCLCover 9 years ago
Expert Explores Treatments for Biomarker-Negative Lung Cancerover 9 years ago
The Significance of Surgery Quality in NSCLCover 9 years ago
Practice-Changing Translational Advances Predicted for NSCLCover 9 years ago
Addressing the Challenges of Treating Non-Driver NSCLCAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Exploring Psilocybin-Assisted Therapy for Cancer Patients' Trauma
2
Investigational Mitochondrial Agent Shows Early Survival Signal in Glioblastoma
3
Understanding the Sequencing Decisions in mCRPC After Progression on ADT/ARPI
4
First Patients Dosed With TLX597-Tx in Trial for mHSPC
5































